RxDoctor Payments DataLook up a doctor →

Thomas Ungarino, MD

Critical Care Medicine · Albany, GANPI 1245297209

Payments from drug & device makers

$12,186in general payments, 2019–2025

Across 461 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$2K
  • Insmed, Inc.$772
  • Boehringer Ingelheim$662
  • Covidien LP$657
  • Johnson & Johnson$593
  • plus $5K from 41 others

What the payments were for

  • Travel & lodging$8457%
  • Food & beverage$8,29368%
  • Education$3,04825%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,186 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$89,073
Medicare patients
369
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate33$373,131
OpsumitMacitentan28$358,804
Orenitram ErTreprostinil Diolamine25$212,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter266$195,845
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$46,602
Ambrisentan12$34,200
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$23,170
Breo ElliptaFluticasone/Vilanterol47$21,081
Spiriva RespimatTiotropium Bromide29$19,053
Combivent RespimatIpratropium/Albuterol Sulfate20$12,665
SymbicortBudesonide/Formoterol Fumarate46$10,671
Roflumilast53$5,477
Albuterol Sulfate HfaAlbuterol Sulfate177$3,952
Arnuity ElliptaFluticasone Furoate19$3,911
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$662$404,84982 claims
Actelion Pharmaceuticals US, Inc.Opsumit$475$358,80428 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$1,717$244,007381 claims
AstraZenecaBreztri Aerosphere, Symbicort$500$57,273111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →